Doxorubicin in stage II–III, intermediate-risk Wilms' tumour
Mené sur 583 patients pédiatriques atteints d'une tumeur de Wilms de stade II ou III, cet essai international de phase III évalue l'efficacité, du point de vue de la survie sans événement à 2 ans, et la toxicité d'une chimiothérapie sans doxorubicine
In The Lancet, Kathy Pritchard-Jones and colleagues from the International Society of Paediatric Oncology (SIOP) report results from their Wilms' tumour 2001 randomised, controlled, non-inferiority study. They recruited 583 children aged 6 months to 18 years with stage II–III, histological intermediate-risk Wilms' tumour who had received 4 weeks of preoperative chemotherapy with vincristine and actinomycin D. They randomly assigned the children (1:1) by a minimisation technique to receive either postnephrectomy combination chemotherapy with vincristine and actinomycin D alone—the experimental treatment—or these two drugs plus doxorubicin (a cardiotoxic chemotherapeutic drug), the standard treatment.
The Lancet , commentaire en libre accès, 2014